KR102487614B1 - 티모신 β4를 포함하는 안약의 제조방법 - Google Patents

티모신 β4를 포함하는 안약의 제조방법 Download PDF

Info

Publication number
KR102487614B1
KR102487614B1 KR1020150182196A KR20150182196A KR102487614B1 KR 102487614 B1 KR102487614 B1 KR 102487614B1 KR 1020150182196 A KR1020150182196 A KR 1020150182196A KR 20150182196 A KR20150182196 A KR 20150182196A KR 102487614 B1 KR102487614 B1 KR 102487614B1
Authority
KR
South Korea
Prior art keywords
thymosin
eye drop
preparing
container
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020150182196A
Other languages
English (en)
Korean (ko)
Other versions
KR20170041109A (ko
Inventor
이시영
강신욱
성지혜
엄태흠
Original Assignee
에이치엘비테라퓨틱스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이치엘비테라퓨틱스 주식회사 filed Critical 에이치엘비테라퓨틱스 주식회사
Publication of KR20170041109A publication Critical patent/KR20170041109A/ko
Application granted granted Critical
Publication of KR102487614B1 publication Critical patent/KR102487614B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B23/00—Noble gases; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A61J1/12—Bag-type containers with means for holding samples of contents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020150182196A 2015-10-06 2015-12-18 티모신 β4를 포함하는 안약의 제조방법 Active KR102487614B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150140489 2015-10-06
KR20150140489 2015-10-06

Publications (2)

Publication Number Publication Date
KR20170041109A KR20170041109A (ko) 2017-04-14
KR102487614B1 true KR102487614B1 (ko) 2023-01-12

Family

ID=58487995

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150182196A Active KR102487614B1 (ko) 2015-10-06 2015-12-18 티모신 β4를 포함하는 안약의 제조방법

Country Status (7)

Country Link
US (1) US10744088B2 (cg-RX-API-DMAC7.html)
EP (1) EP3342398B1 (cg-RX-API-DMAC7.html)
JP (2) JP6996713B2 (cg-RX-API-DMAC7.html)
KR (1) KR102487614B1 (cg-RX-API-DMAC7.html)
ES (1) ES3064258T3 (cg-RX-API-DMAC7.html)
HK (1) HK1256595A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017061663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12653779B2 (en) 2015-06-18 2026-06-16 Lenz Therapeutics Operations, Inc. Compositions and methods for the treatment of presbyopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN115266995B (zh) * 2022-08-02 2023-10-13 兆科（广州）眼科药物有限公司 一种生发肽制剂中有关物质的分析方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
KR19980703582A (ko) * 1995-04-04 1998-11-05 가와구치 시게키 염산 프로카테롤 수용액 제제를 보지하는 패키지 및 염산 프로카테롤 수용액 제제
EP1100529B2 (en) 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US6552198B1 (en) 1998-10-14 2003-04-22 Kyowa Hakko Kogyo Co., Ltd. Method of stabilizing aqueous pyrazoloacridone derivative solution
MY176923A (en) * 2004-07-30 2020-08-26 Otsuka Pharma Co Ltd Squeeze bottle and eye dropper using the same
KR20060051135A (ko) 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
KR20080018268A (ko) * 2005-06-17 2008-02-27 리지너크스 바이오 파마소티컬스, 인코포레이티드 조직 악화, 부상 또는 손상을 치료하거나 또는 예방하기위한 엘케이케이티이티 및/또는 엘케이케이티엔티 조성물들및 그 방법
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
WO2008108927A2 (en) * 2007-03-06 2008-09-12 Regenerx Biopharmaceuticals, Inc. Methods and compositions for stabilizing polypeptides
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法

Also Published As

Publication number Publication date
EP3342398A1 (en) 2018-07-04
JP2020183391A (ja) 2020-11-12
HK1256595A1 (en) 2019-09-27
US20180228729A1 (en) 2018-08-16
US10744088B2 (en) 2020-08-18
ES3064258T8 (en) 2026-05-13
ES3064258T3 (en) 2026-04-23
JP2018531905A (ja) 2018-11-01
EP3342398B1 (en) 2026-02-11
EP3342398A4 (en) 2019-03-20
JP6996713B2 (ja) 2022-02-04
KR20170041109A (ko) 2017-04-14
EP3342398C0 (en) 2026-02-11
WO2017061663A1 (ko) 2017-04-13

Similar Documents

Publication Publication Date Title
EP3342398B1 (en) Method for preparing ophthalmic preparation containing thymosin beta-4
JP7531564B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
EP0838221B1 (en) Lyophilized hgf preparations
EP1180368B1 (en) Freeze dried hgf preparations
US10463708B2 (en) Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
US10293045B2 (en) Stable liquid formulations of recombinant fusion proteins
US10071136B2 (en) Stable liquid formulations of recombinant fusion proteins
EP3643784A1 (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
NO319174B1 (no) Lyofilisert tilberedningsform av en transglutaminase samt anvendelse av denne
JPH10212241A (ja) Ｂｄｎｆを安定に含有する製剤
US20190381136A1 (en) Stable peptide compositions
CN1315531C (zh) 用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
EP2478010B1 (en) Partial peptide of lacritin
KR20090118030A (ko) Ｈｇｆ 제제
EP2496246B1 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
US9254306B2 (en) Eye drops
KR20230117342A (ko) 펩타이드 제제 및 이의 안과적 용도
ES2261977T3 (es) Fraccion de albumina derivada de plasma empobrecido en precalicreina.
JPH10265404A (ja) ヒト成長ホルモンを含有する医薬製剤
US20240059768A1 (en) A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer
CN111344300B (zh) Pacap的稳定化肽
EP4475866A1 (en) Peptides and methods of use thereof in treating ocular disorders
AU2005200353B2 (en) Lyophilized HGF preparations

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4